An antibody to the interleukin-6 receptor in development for the treatment of rheumatoid arthritis in collaboration with Sanofi.

Development Phase: Phase 3 in rheumatoid arthritis.

This section discusses pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been evaluated by any regulatory authorities for the indications described in this section.